A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

BACKGROUND: Myelotoxicity during initial cycles of chemotherapy for Hodgkin lymphoma is associated with better outcome, supporting the concept of individualised dosing based on pharmacodynamic end points to optimise results. This study was performed to identify the maximum tolerated dose (MTD) of do...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Gibb, A, Greystoke, A, Ranson, M, Linton, K, Neeson, S, Hampson, G, Illidge, T, Smith, E, Dive, C, Pettitt, A, Lister, A, Johnson, P, Radford, J
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2013
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3833204/
https://ncbi.nlm.nih.gov/pubmed/24136151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.605
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia